Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 9/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.45 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | HINT1 | P49773 | 1/20 | 0.42 |
| ▸ | CD99 | P14209 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15868495 | 1.00 | HPGD (0.47) | HPGDNT5EIMPDH2IMPDH1PDE2A | |
| SCHEMBL14928630 | 1.00 | HPGD (0.47) | HPGDNT5EIMPDH2IMPDH1PDE2A | |
| SCHEMBL15044563 | 1.00 | HPGD (0.47) | HPGDNT5EIMPDH2IMPDH1PDE2A | |
| SCHEMBL17930335 | 0.92 | HPGD (0.56) | HPGDNT5EIMPDH2IMPDH1TAS1R3 | |
| SCHEMBL15249110 | 0.92 | HPGD (0.56) | HPGDNT5EIMPDH2IMPDH1TAS1R3 | |
| SCHEMBL15044597 | 0.91 | HPGD (0.47) | HPGDNT5EIMPDH2IMPDH1TAS1R3 | |
| SCHEMBL14928632 | 0.91 | HPGD (0.47) | HPGDNT5EIMPDH2IMPDH1TAS1R3 | |
| SCHEMBL15868521 | 0.91 | HPGD (0.47) | HPGDNT5EIMPDH2IMPDH1TAS1R3 | |
| SCHEMBL14928876 | 0.90 | HPGD (0.46) | HPGDNT5EIMPDH2IMPDH1TAS1R3 | |
| SCHEMBL18852352 | 0.90 | HPGD (0.48) | HPGDNT5EIMPDH2IMPDH1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | HPGD 4560/4885NT5E 67/4885IMPDH2 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.